A5073116106- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Immune Cell Function and Interaction
- Sepsis Diagnosis and Treatment
- Kawasaki Disease and Coronary Complications
- Inflammation biomarkers and pathways
- Inflammasome and immune disorders
- Childhood Cancer Survivors' Quality of Life
- Neonatal and Maternal Infections
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Clinical Reasoning and Diagnostic Skills
- SARS-CoV-2 and COVID-19 Research
- IL-33, ST2, and ILC Pathways
- Immunodeficiency and Autoimmune Disorders
- Bone health and treatments
- Complement system in diseases
- Neutropenia and Cancer Infections
- T-cell and B-cell Immunology
- Sarcoidosis and Beryllium Toxicity Research
- Asthma and respiratory diseases
- Parvovirus B19 Infection Studies
- Liver Disease and Transplantation
- Bone and Joint Diseases
National Institute of Allergy and Infectious Diseases
2019-2024
National Institutes of Health
2019-2024
St. Jude Children's Research Hospital
2021
Children's Hospital of Pittsburgh
2018
PRA Health Sciences
2018
George Washington University Hospital
2017
George Washington University
2015-2016
Temple University
2013-2015
Kulicke & Soffa (United States)
2015
University of Alabama at Birmingham
2011-2013
To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival sepsis patients with features macrophage activation syndrome. Despite equivocal results trials, is effective treating syndrome, a similar entity fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, syndrome may benefit from blockade. Reanalysis deidentified data phase III randomized antagonist trial severe sepsis....
To describe the clinical, laboratory, and histopathologic features, current treatment, outcome of patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA).In this multinational, multicenter study, pediatric rheumatologists hemato-oncologists entered patient data collected retrospectively into a web-based database.A total 362 patients, 22% whom had MAS at onset JIA, were included in study by 95 investigators from 33 countries. The most...
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute disease severity of 2019 (COVID-19). However, the utility specific immune-based biomarkers predict clinical outcome remains elusive. Here, we analyzed levels 66 soluble in 175 Italian patients with COVID-19 ranging from mild/moderate critical assessed type I IFN–, II NF-κB–dependent whole-blood transcriptional signatures. A broad signature was observed, implicating activation various...
We hypothesize that three inflammation pathobiology phenotypes are associated with increased inflammation, proclivity to develop features of macrophage activation syndrome, and multiple organ failure-related death in pediatric severe sepsis.Prospective cohort study comparing children sepsis any phenotypes: 1) immunoparalysis-associated failure (whole blood ex vivo tumor necrosis factor response endotoxin < 200 pg/mL), 2) thrombocytopenia-associated (new onset thrombocytopenia acute kidney...
Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome that often requires critical care support and remains difficult to diagnose. These guidelines are meant aid in the early recognition, diagnosis, supportive care, treatment of patients with hemophagocytic ICUs.The literature searches were performed PubMed (MEDLINE).Keywords medical subject headings terms for search included "macrophage activation syndrome," lymphohistiocytosis," "hemophagocytic syndrome."The Histiocyte Society...
Objectives: We tested the hypothesis that a C -reactive protein and ferritin-based systemic inflammation contingency table can track mortality risk in pediatric severe sepsis. Design: Prospective cohort study. Setting: Tertiary PICU. Patients: Children with 100 separate admission episodes of sepsis were enrolled. Interventions: Blood samples attained on day 2 bi-weekly for biomarker batch analysis. A × using ferritin thresholds was developed. Measurements Main Results: 4.08 mg/dL 1,980 ng/mL...
Interleukin-1 receptor antagonists can reduce mortality in septic shock patients with hepatobiliary dysfunction and disseminated intravascular coagulation (HBD + DIC), an organ failure pattern inflammatory features consistent macrophage activation. Identification of clinical phenotypes sepsis may allow for improved care. We aim to describe the occurrence HBD DIC a contemporary cohort determine association this phenotype known activation syndrome (MAS) biomarkers mortality. performed...
Introduction: Adult hemophagocytic syndrome (HPS) is a fulminant, fatal form of MODS, sharing features and markers severe sepsis [fever, coagulopathy, hepatobiliary dysfunction (HBD), cytopenias, hyperferritinemia, central nervous system increased expression CD163]. Despite the equivocal results IL-1 receptor blockade in sepsis, IL-1ra (anakinra) has been an effective part treatment pediatric adult by targeting driven cytokine upregulation. Methods: A post hoc analysis de-identified data...
Belimumab is a human genome derived monoclonal antibody with specificity for BLyS (B lymphocyte stimulator, or B-cell activating factor [BAFF]), cytokine that promotes the survival and maturation of B cells into antibody-secreting plasmablasts. Recent phase III clinical trials belimumab in patients active systemic lupus erythematosus (SLE) have been completed achieved primary efficacy endpoints employing validated disease activity measures (SLEDAI BILAG) as well additional secondary related...
Background Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that occur in many contexts often called by names. They nevertheless can progress rapidly, early identification management critical for preventing organ failure mortality. Objectives The purpose of this effort was to develop a series ‘points consider’ assist clinicians at the earliest stages evaluation diagnosis, management, monitoring...
Copyright © by 2015 the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.